Authors
Shen Lao, Zisheng Chen, Yuan Zhang, Jianfu Li, Hengrui Liang, Yongmei Zheng, Xiaoyan Liu, Wei Wang, Wenhua Liang
Published in
Translational lung cancer research. Volume 15. Issue 4. Pages 90. Apr 30, 2026. Epub Mar 19, 2026.
Abstract
Research has increasingly shown that lipid metabolism contributes to lymph node metastasis (LNM) and the progression of cancer. This study investigates the role of lipid metabolism in LNM of lung adenocarcinoma (LUAD).
We gathered clinicopathological data and RNA-sequencing information from LUAD patients using The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. We identified differentially expressed lipid metabolism-related genes (LMRGs) in LUAD with and without LNM. Using a prognostic risk scoring system, we correlated LMRGs with clinicopathological outcomes, genomic alterations, immune features, immunotherapy responses, and drug susceptibility.
A three-gene lipid metabolic signature (GPD1L, SPHK1, and ST3GAL4) associated with LNM and tumor progression was identified. High-risk patients exhibited worse overall survival (OS), increased infiltration of M0 macrophages and degranulating mast cells, and were more likely to be non-responsive to immunotherapy. Additionally, the high-risk group showed higher tumor mutation burden (TMB) and programmed death-ligand 1 (PD-L1) expression, suggesting a potential benefit from combined immunotherapy and LMRG-targeted therapy. Differentially expressed genes (DEGs) in the high-risk group were enriched in the reactive oxygen species pathway.
Our findings provide new insights into the molecular mechanisms underlying regional metastasis in LUAD related to lipid metabolism and highlight the potential for precision therapies targeting this pathway.
PMID:
42170252
Bibliographic data and abstract were imported from PubMed on 15 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 9
- Comments 0